Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.68 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciluprevir SCHEMBL5152276 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL2524642 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL16199312 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL1735179 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL18671856 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL16438974 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL5152261 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL1736294 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| Ciluprevir SCHEMBL12300089 | 0.95 | ADRB3 (0.75) | ADRB3ADRA2BADRA2CCTSBCTSS | |
| SCHEMBL7876062 | 0.93 | ADRB3 (0.64) | ADRB3ADRA2BADRA2CCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | ADRB3 4070/4885ADRA2B 4543/4885ADRA2C 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.